Cytokinetics, Inc.

611 articles with Cytokinetics, Inc.

• Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session

  3/4/2023

  Cytokinetics, Incorporated announced that positive results from Cohort 4 of REDWOOD-HCM, a Phase 2 clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy, were presented at the American College of Cardiology 72nd Annual Scientific Session.

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 02, 2023

  3/2/2023

  Cytokinetics, Incorporated announced that on February 28, 2023 it granted stock options to purchase an aggregate of 21,450 shares of common stock to 5 new employees, whose employment commenced in February 2023, as a material inducement to their employment.

• 

  FDA Rejects Cytokinetics’ Heart Failure Drug, Requests Another Trial

  3/1/2023

  Citing lack of efficacy evidence, the FDA rejected Cytokinetics’ heart failure hopeful omecamtiv mecarbil in a decision announced Tuesday evening.

• Cytokinetics Reports Fourth Quarter 2022 Financial Results

  3/1/2023

  Cytokinetics, Incorporated reported financial results for the fourth quarter and full year 2022. Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2022 was $389.0 million or $4.33 per share.

• Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil

  2/28/2023

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction (HFrEF).

• 

  FDA Action Alert: Cytokinetics, Reata, Regeneron, Pfizer and GSK

  2/27/2023

  The FDA is expected to cap off February with a trio of verdicts, including one for a heart failure treatment and another potential first approval for a rare, neurodegenerative disease.

• Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session

  2/24/2023

  Cytokinetics, Incorporated announced three poster presentations at the American College of Cardiology 72nd Annual Scientific Session taking place in New Orleans, LA from March 4, 2023 – March 6, 2023.

• Cytokinetics to Announce Fourth Quarter Results on March 1, 2023

  2/15/2023

  Cytokinetics, Incorporated announced that it is scheduled to report fourth quarter results on March 1, 2023 at 4:00 PM Eastern Time.

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2023

  2/1/2023

  Cytokinetics, Incorporated announced that on January 31, 2023 it granted stock options to purchase an aggregate of 87,600 shares of common stock to 13 new employees, whose employment commenced in January 2023, as a material inducement to their employment.

• Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant ProgramTotal of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach

  1/30/2023

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its fifth annual Communications Grant Program, intended to support communications, awareness building and community engagement for nonprofit organizations serving the patient community.

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2023

  1/4/2023

  Cytokinetics, Incorporated announced that on December 30, 2022 it granted stock options to purchase an aggregate of 130,000 shares of common stock to 6 new employees, whose employment commenced in December 2022, as a material inducement to their employment.

• Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 AM Pacific Time at the Westin St. Francis Hotel in San Francisco.

• 

  FDA Adcomm Votes Against Cytokinetics’ Heart Failure Drug

  12/14/2022

  The FDA’s Cardiovascular and Renal Drugs Advisory Committee stood against Cytokinetics, Inc., finding that the benefits of its heart failure hopeful didn’t outweigh its risks.

• Cytokinetics Stock Trading Halted Today

  12/13/2022

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Nasdaq has halted the trading of the Company’s common stock.

• Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

  12/13/2022

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction (HFrEF).

• Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil

  12/9/2022

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to review the New Drug Application (NDA) for omecamtiv mecarbil, an investigational selective, small molecule cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF).

• Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND

  12/8/2022

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data were presented at the Virtual 33rd International Symposium on ALS/MND related to survival predictions from FORTITUDE-ALS.

• Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility

  12/7/2022

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose clinical study of CK-3828136 (CK-136), formerly known as AMG 594.

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022

  12/2/2022

  Cytokinetics, Incorporated announced that on November 30, 2022 it granted stock options to purchase an aggregate of 146,100 shares of common stock to 14 new employees, whose employment commenced in November 2022, as a material inducement to their employment.

• Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND

  12/1/2022

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one poster presentation at the Virtual 33rd International Symposium on ALS/MND taking place online from December 6, 2022 - December 9, 2022 relating to survival predictions from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in ALS.